Drugs in R & D

, Volume 6, Issue 4, pp 249–252 | Cite as


CGP 33101, E 2080, RUF 331, Xilep
Adis R&D Profile


Placebo Recipient Adjunctive Therapy Partial Seizure Seizure Frequency Rufinamide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Eisai Co Ltd. Eisai Announces In-Licensing Agreement with Novartis for Rufinamide, A New Antiepileptic Agent. Media Release: 9 Feb 2004. Available from URL: Google Scholar
  2. 2.
    Eisai Co Ltd. Eisai Announces Submission of Marketing Authorization Application of the Anti-epileptic Agent Inovelon in Europe. Media Release: 30 Mar 2005. Available from URL: Google Scholar
  3. 3.
    Cheung WK, Kianifard F, Wong A, et al. Intra- and inter-subject variabilities of CGP 33101 after replicate single oral doses of two 200-mg tablets and 400-mg suspension. Pharmaceutical Research 12: 1878–1882, Dec 1995PubMedCrossRefGoogle Scholar
  4. 4.
    Waldmeier F, Gschwind H-P, Rouan M-C. Metabolism of the new anticonvulsive trial drug rufinamide (CGP 33101) in healthy male volunteers. Epilepsia 37 (Suppl. 5): 167, 1996Google Scholar
  5. 5.
    Pålhagen S, Canger R, Henriksen O, et al. Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy. Epilepsy Research 43: 115–124, Feb 2001PubMedCrossRefGoogle Scholar
  6. 6.
    Chang S-W, Choi L, Karoplchyk MA. A pharmacokinetic evaluation of rufinamide in elderly and younger subjects. Epilepsia 39 (Suppl. 6): 59, 1998Google Scholar
  7. 7.
    Sachdeo RC, Rosenfeld WE, Choi L. Pharmacokinetics and safety of adjunctive rufinamide therapy in pediatric patients with epilepsy. Epilepsia 39 (Suppl. 6): 166–167, 1998Google Scholar
  8. 8.
    Litzinger MJ, Hanny A. Safety and efficacy of open-label rufinamide as adjunctive therapy in pediatric patients with partial seizures. Epilepsia 40 (Suppl. 7): 114 (plus poster), 1999Google Scholar
  9. 9.
    Vazquez BR, Sachedo R, Maxoutova AL, et al. Efficacy and safety of rufinamide as adjunctive therapy in adult patients with therapy-resistant partial-onset seizures. Epilepsia 41 (Suppl. 7): 255, 2000Google Scholar
  10. 10.
    Kapeghian JC, Madan A, Parkinson A. Evaluation of rufinamide (CGP 33101), a novel anticonvulsant, for potential drug interactions in vitro. Epilepsia 37 (Suppl. 5): 26, 1996Google Scholar
  11. 11.
    Svendsen KD, Choid L, Chen B-L. Single-center, open-label, multiple-dose pharmacokinetic trial investigating the effect of rufinamide administration on Ortho-Novum 1/35 in healthy women. Epilepsia 39 (Suppl. 6): 59, 1998Google Scholar

Copyright information

© Adis Data Information BV 2005

Personalised recommendations